Novimmune

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Novimmune is a privately held Swiss pharmaceutical development company focusing on monoclonal antibody therapies for treatment of immune-related diseases. The company was founded in 19981. Novimmune has six publicly disclosed drug in their pipeline: * NI-0101, an anti-TLR4 antibody being developed in partnership with Genentech. A phase I clinical trial was completed in 2014 and phase II trials are expected to begin in early 2017. * NI-0401, an anti-CD3ε antibody being developed in partnership with Tiziana Life Sciences. Phase II trials in patients with Crohn's disease and transplant rejection finished in 2008 and 2009, respectively. * NI-0501, an anti-IFNγ antibody, is in development for hemophagocytic lymphohistiocytosis. A phase II/III trial began in 2013 and is ongoing. The FDA awarded breakthrough status to the drug in 2016. * NI-1401, an anti-IL17 drug being developed in partnership with Genentech for inflammatory and auto-immune diseases. * NI-1701, an anti-CD47, anti-CD19 bispecific antibody in development for treatment of B-cell hematological cancers. * NI-1801, an anti-CD47, anti-mesothelin bispecific antibody in the preclinical phase of development for treatment of solid tumors. No drugs have been approved yet.

Novimmune is a privately held Swiss pharmaceutical development company focusing on monoclonal antibody therapies for treatment of immune-related diseases. The company was founded in 1998. Novimmune has six publicly disclosed drug in their pipeline: NI-0101, an anti-TLR4 antibody being developed in partnership with Genentech. A phase I clinical trial was completed in 2014 and phase II trials are expected to begin in early 2017. NI-0401, an anti-CD3ε antibody being developed in partnership with Tiziana Life Sciences. Phase II trials in patients with Crohn's disease and transplant rejection finished in 2008 and 2009, respectively. NI-0501, an anti-IFNγ antibody, is in development for hemophagocytic lymphohistiocytosis. A phase II/III trial began in 2013 and is ongoing. The FDA awarded breakthrough status to the drug in 2016. NI-1401, an anti-IL17 drug being developed in partnership with Genentech for inflammatory and auto-immune diseases. NI-1701, an anti-CD47, anti-CD19 bispecific antibody in development for treatment of B-cell hematological cancers. NI-1801, an anti-CD47, anti-mesothelin bispecific antibody in the preclinical phase of development for treatment of solid tumors. No drugs have been approved yet.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1314574453 under CC BY-SA 4.0; modifications have been made.

References

  1. ↩Wikipedia “Novimmune” revision 1314574453 · retrieved 2026-10-20 date of foundation (×1) · confidence 0.95 revision URL

Provenance

snapshot enwiki-001314574453 · captured 1759371734.0 · version history

Cite this page as: encyclopegia.org, “Novimmune”, snapshot enwiki-001314574453. https://encyclopegia.org/a/novimmune